[Psoriatic erythroderma treated with etanercept].
Piqué-Duran
E
E
Pérez-Cejudo
J A
JA
D000368:Aged; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D003873:Dermatitis, Exfoliative / Q000188:drug therapy* / Q000209:etiology; D000068800:Etanercept; D005260:Female; D005334:Fever / Q000209:etiology; D005440:Fluid Therapy; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D016572:Cyclosporine; D000068800:Etanercept